| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Loss on derivative liability | -100 | - | ||
| Total other income (expense), net | -84 | 1,224 | ||
| Net loss before income taxes | -7,488 | - | ||
| Benefit from deferred income taxes | -1,088 | - | ||
| Net loss | -6,400 | -1,895 | ||
| Foreign currency translation adjustment | -38 | -333 | ||
| Total other comprehensive (loss) income, net of tax | -38 | -333 | ||
| Total comprehensive loss | -6,438 | -2,228 | ||
| Net loss per share - basic | 0 | 0 | ||
| Net loss per share - diluted | 0 | 0 | ||
| Weighted-average number of ordinary shares used in computing net loss per share - basic | 65,326,236,698 | 62,943,895,665 | ||
| Weighted-average number of ordinary shares used in computing net loss per share - diluted | 65,326,236,698 | 62,943,895,665 | ||
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)